Changes After Suprachoroidal Injection.
Changes Noted After Suprachoroidal Triamcinolone Acetonide Injection.
1 other identifier
interventional
30
1 country
1
Brief Summary
Changes after suprachoroidal injection are analyzed for statistical analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 15, 2022
CompletedFirst Submitted
Initial submission to the registry
March 11, 2022
CompletedFirst Posted
Study publicly available on registry
March 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2022
CompletedMarch 21, 2022
March 1, 2022
7 months
March 11, 2022
March 11, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Changes in visual acuity
Changes in best corrected visual acuity after injection
Monthly after injection till six months of follow up
Changes in central foveal thickness
Changes in central macular thickness after injection
Monthly after injection till six months of follow up
Secondary Outcomes (2)
Changes in intraocular pressure
Monthly after injection till six months of follow up
Changes in lens
Monthly after injection till six months of follow up
Study Arms (2)
Suprachoroidal triamcinolone injection
ACTIVE COMPARATOREyes treated with suprachoroidal injection of triamcinolone acetonide.
Non-treated eyes
NO INTERVENTIONEyes that are receiving no interventions during the study period.
Interventions
Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
Eligibility Criteria
You may qualify if:
- Patients prepared to suprachoroidal injection for various retinal diseases will be enrolled in the study.
- Bilateral retinal diseases that required interventions as diabetic macular edema, exudative retinal detachment, and serous chorioretinopathies.
You may not qualify if:
- Other retinal diseases that are not expected to improve after steroid injections as central retinal artery occlusion and age-related macular degenerations.
- Choroidal neovascularization that require anti-vascular endothelial growth factors.
- Patients refused to have steroid injections even after discussing the nature of their disease with them and the procedure to be done.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Benha Universitylead
Study Sites (1)
Benha University
Banhā, QA, 13511, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ahmed A Tabl, MD
Benha University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of Ophthalmology
Study Record Dates
First Submitted
March 11, 2022
First Posted
March 21, 2022
Study Start
February 15, 2022
Primary Completion
August 30, 2022
Study Completion
September 1, 2022
Last Updated
March 21, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share